SCHEMBL5320524

SCHEMBL5320524

NC(Cc1c(Br)cc(O)cc1Br)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 3/20 0.50
USP2 O75604 3/20 0.49
ALOX15 P16050 3/20 0.49
HSD17B10 Q99714 3/20 0.49
KDM4E B2RXH2 3/20 0.49
HIF1A Q16665 2/20 0.49
RECQL P46063 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
PKM P14618 2/20 0.49
THRB P10828 2/20 0.49
CYP3A4 P08684 2/20 0.49
NFKB1 P19838 2/20 0.49
ALDH1A1 P00352 2/20 0.49
LMNA P02545 2/20 0.49
MAPT P10636 2/20 0.49
BLM P54132 2/20 0.49
PMP22 Q01453 2/20 0.49
KMT2A Q03164 2/20 0.49
NPSR1 Q6W5P4 2/20 0.49
RGS12 O14924 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5320527 1.00 SLC7A5 (0.50) SLC7A5USP2ALOX15HSD17B10KDM4E
SCHEMBL5323250 0.81 USP2 (0.49) SLC7A5USP2ALOX15HSD17B10KDM4E
SCHEMBL5323246 0.81 USP2 (0.49) SLC7A5USP2ALOX15HSD17B10KDM4E
SCHEMBL5287199 0.80 USP2 (0.47) SLC7A5USP2ALOX15HSD17B10KDM4E
SCHEMBL5324409 0.79 SIRT5 (0.59) SLC7A5USP2ALOX15HSD17B10KDM4E
SCHEMBL5324405 0.79 SIRT5 (0.59) SLC7A5USP2ALOX15HSD17B10KDM4E
SCHEMBL296690 0.78 SLC7A5 (0.50) SLC7A5USP2ALOX15HSD17B10KDM4E
SCHEMBL5327701 0.78 SLC7A5 (0.50) SLC7A5USP2ALOX15HSD17B10KDM4E
SCHEMBL296983 0.78 USP2 (0.53) SLC7A5USP2ALOX15HSD17B10KDM4E
SCHEMBL296982 0.78 USP2 (0.53) SLC7A5USP2ALOX15HSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070258899-A1 Diagnostic and therapeutic agents KARYON-CTT LTD (FI) 2007-11-08 US disclosed
WO-2007113385-A1 DIAGNOSTIC AND THERAPEUTIC AGENTS KARYON-CTT LTD (FI) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070258899-A1 Diagnostic and therapeutic agents YBX1, MLX, TPX2 SLC7A5 3712/4885USP2 3792/4885ALOX15 4182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.